ASND — Ascendis Pharma A/S Share Price
0.000.00%
Last trade - 00:00- $8.43bn
- $8.69bn
- €266.72m
- 30
- 17
- 88
- 41
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 29.69 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -72.51% | ||
| Return on Equity | -818.43% | ||
| Operating Margin | -170.79% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 13.38 | 6.95 | 7.78 | 51.17 | 266.72 | 433.36 | 740.1 | 90.68% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Directors
- Michael Jensen CHM (50)
- Jan Moller Mikkelsen PRE (61)
- Scott Smith CFO (47)
- Lotte Soenderbjerg SVP (59)
- Mark Bach SVP (64)
- Vibeke Breinholt SVP (54)
- Jesper Hoiland SVP (60)
- Flemming Jensen SVP (59)
- Jens Okkels SVP (60)
- Dana Pizzuti SVP (65)
- Juha Punnonen SVP (55)
- Kennett Sprogoee SVP (42)
- Peter Rasmussen CAO (52)
- Lisa Bright IND (53)
- Albert Cha IND (49)
- James Healy IND (55)
- Lars Holtug IND (62)
- Birgitte Volck IND (58)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- September 21st, 2006
- Public Since
- January 28th, 2015
- No. of Shareholders
- 3
- No. of Employees
- 879
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 57,707,439
- Address
- Tuborg Boulevard 12, HELLERUP, 2900
- Web
- https://ascendispharma.dk/
- Phone
- Contact
- Scott Smith
- Auditors
- Deloitte Statsautoriseret Revisionspartnerselskab
Upcoming Events for ASND
Q2 2024 Ascendis Pharma A/S Earnings Release
Similar to ASND
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Ascendis Pharma A/S share price?
As of Today at 19:02 UTC, shares in Ascendis Pharma A/S are trading at $146.04. This share price information is delayed by 15 minutes.
How has the Ascendis Pharma A/S share price performed this year?
Shares in Ascendis Pharma A/S last closed at $146.04 and the price had moved by +76.87% over the past 365 days. In terms of relative price strength the Ascendis Pharma A/S share price has outperformed the S&P500 Index by +42.84% over the past year.
What are the analyst and broker recommendations for Ascendis Pharma A/S?
The overall consensus recommendation for Ascendis Pharma A/S is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Ascendis Pharma A/S dividend yield?
Ascendis Pharma A/S does not currently pay a dividend.
Does Ascendis Pharma A/S pay a dividend?
Ascendis Pharma A/S does not currently pay a dividend.
When does Ascendis Pharma A/S next pay dividends?
Ascendis Pharma A/S does not currently pay a dividend.
How do I buy Ascendis Pharma A/S shares?
To buy shares in Ascendis Pharma A/S you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Ascendis Pharma A/S?
As of the previous close price of $146.04, shares in Ascendis Pharma A/S had a market capitalisation of $8.43bn.
Where are Ascendis Pharma A/S shares listed?
Here are the trading details for Ascendis Pharma A/S:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ASND
What kind of share is Ascendis Pharma A/S?
Based on an overall assessment of its quality, value and momentum Ascendis Pharma A/S is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Ascendis Pharma A/S share price forecast for 2024?
The analyst consensus target price for shares in Ascendis Pharma A/S is $178.21. That is 22.03% above the last closing price of $146.04.
Analysts covering Ascendis Pharma A/S currently have a consensus Earnings Per Share (EPS) forecast of -€4.50 for the next financial year.
What is the trend in the Ascendis Pharma A/S share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ascendis Pharma A/S. Over the past six months, its share price has outperformed the S&P500 Index by +33.23%.
As of the last closing price of $146.04, shares in Ascendis Pharma A/S were trading +29% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Ascendis Pharma A/S PE Ratio?
The Ascendis Pharma A/S PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $146.04.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Ascendis Pharma A/S?
Ascendis Pharma A/S' management team is headed by:
- Michael Jensen - CHM
- Jan Moller Mikkelsen - PRE
- Scott Smith - CFO
- Lotte Soenderbjerg - SVP
- Mark Bach - SVP
- Vibeke Breinholt - SVP
- Jesper Hoiland - SVP
- Flemming Jensen - SVP
- Jens Okkels - SVP
- Dana Pizzuti - SVP
- Juha Punnonen - SVP
- Kennett Sprogoee - SVP
- Peter Rasmussen - CAO
- Lisa Bright - IND
- Albert Cha - IND
- James Healy - IND
- Lars Holtug - IND
- Birgitte Volck - IND